#United States #Redwood City #Lung Cancer #Aliya PEF #Galvanize Therapeutics

Introducing Aliya® Pulsed Electric Field Ablation

Recent research published in the medical journal Cancers has showcased the promising results of Aliya® Pulsed Electric Field (PEF) ablation in patients suffering from metastatic lung cancer. Conducted by Galvanize Therapeutics, Inc., this non-invasive treatment demonstrates a high efficacy in controlling lung tumors in stage IV non-small cell lung cancer (NSCLC) or lung metastasis patients.

Overview of the Study

The AFFINITY clinical trial, a six-month study involving a total of 28 evaluable patients, aimed to determine the safety and feasibility of Aliya PEF ablation. This groundbreaking therapy is designed to be performed endoscopically and focuses on ensuring that patients who undergo this procedure are still eligible for further standard-of-care treatments.

Dr. Michael A. Pritchett, one of the study's investigators and the Director of the Chest Center of the Carolinas, has emphasized the significance of the strong local control rates displayed in the trial. The results indicate that Aliya® PEF ablation achieved remarkable local control rates, with 94% success in patients receiving additional therapies and 100% among those who did not.

Safety and Efficacy Outcomes

The findings from the AFFINITY trial are particularly noteworthy:

• - Safety Profile: The PEF ablation procedure was delivered successfully to all participants, showcasing its well-tolerated nature with minimal complications—only one serious event was reported, which resolved without lasting consequences.
• - Local Tumor Control: An impressive 96% of patients achieved local tumor control, validating the effectiveness of the treatment.
• - Immune Activation: This study also uncovered potential indications that Aliya PEF ablation could boost systemic immune activation, a critical aspect for patients who are not surgical candidates.

Dr. Pritchett remarked, “These findings are encouraging, as they suggest that Aliya PEF not only maintains strong local control of tumors but may also elicit a favorable immune response in patients.” This dual effect creates an opportunity for the treatment to be used alongside immunotherapy, potentially enhancing treatment outcomes for patients fighting advanced cancer.

Innovative Approach to Tumor Treatment

What sets Aliya PEF apart from traditional ablation methods is its unique approach. Instead of using thermal energy, Aliya employs high-voltage electrical pulses that induce targeted cell death while minimizing damage to surrounding tissues. This refinement in technique exemplifies a significant evolution in oncology treatments, emphasizing precision while preserving the integrity of healthy structures.

The Aliya PEF System and its accompanying INUMI™ Flex needle have received 510(k) clearance in the United States, enabling a safer and more efficient treatment option for a wider range of patients. Over 2,000 patients have experienced the benefits of Aliya PEF ablation, both in clinical trials and as part of commercial applications.

A Vision for the Future

Galvanize Therapeutics aspires to lead the charge in medical technology innovations that not only treat diseases like cancer and chronic lung conditions but also improve the quality of life for patients across the spectrum. CEO Doug Godshall expressed their commitment, stating, “We aim to enhance patient lives through continuous investment in research and validation of Aliya PEF’s capabilities.”

In conclusion, the promising results of the AFFINITY study demonstrate that Aliya® Pulsed Electric Field Ablation could be a transformative treatment alternative in the fight against metastatic lung cancer, ushering in a new era of targeted therapies that leverage both local control and systemic immune activation.